BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 23204225)

  • 1. Targeting folate receptors to treat invasive urinary bladder cancer.
    Dhawan D; Ramos-Vara JA; Naughton JF; Cheng L; Low PS; Rothenbuhler R; Leamon CP; Parker N; Klein PJ; Vlahov IR; Reddy JA; Koch M; Murphy L; Fourez LM; Stewart JC; Knapp DW
    Cancer Res; 2013 Jan; 73(2):875-84. PubMed ID: 23204225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNMT1: an emerging target in the treatment of invasive urinary bladder cancer.
    Dhawan D; Ramos-Vara JA; Hahn NM; Waddell J; Olbricht GR; Zheng R; Stewart JC; Knapp DW
    Urol Oncol; 2013 Nov; 31(8):1761-9. PubMed ID: 22609058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of folate receptor expression and folate uptake in multicentric lymphomas in dogs.
    Childress MO; Dhawan D; Leamon CP; Miller MA; Ramos-Vara JA; Naughton JF; Low PS; Knapp DW
    Am J Vet Res; 2014 Feb; 75(2):187-94. PubMed ID: 24471755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I/II clinical trial of the targeted chemotherapeutic drug, folate-tubulysin, in dogs with naturally-occurring invasive urothelial carcinoma.
    Szigetvari NM; Dhawan D; Ramos-Vara JA; Leamon CP; Klein PJ; Ruple AA; Heng HG; Pugh MR; Rao S; Vlahov IR; Deshuillers PL; Low PS; Fourez LM; Cournoyer AM; Knapp DW
    Oncotarget; 2018 Dec; 9(97):37042-37053. PubMed ID: 30651934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cisplatin versus cisplatin combined with piroxicam in a canine model of human invasive urinary bladder cancer.
    Knapp DW; Glickman NW; Widmer WR; DeNicola DB; Adams LG; Kuczek T; Bonney PL; DeGortari AE; Han C; Glickman LT
    Cancer Chemother Pharmacol; 2000; 46(3):221-6. PubMed ID: 11021739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Folate receptor-specific antitumor activity of EC131, a folate-maytansinoid conjugate.
    Reddy JA; Westrick E; Santhapuram HK; Howard SJ; Miller ML; Vetzel M; Vlahov I; Chari RV; Goldmacher VS; Leamon CP
    Cancer Res; 2007 Jul; 67(13):6376-82. PubMed ID: 17616697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cisplatin treatment of transitional cell carcinoma of the urinary bladder in dogs: 18 cases (1983-1993).
    Chun R; Knapp DW; Widmer WR; Glickman NW; DeNicola DB; Bonney PL
    J Am Vet Med Assoc; 1996 Nov; 209(9):1588-91. PubMed ID: 8899023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo imaging of folate receptor positive tumor xenografts using novel 68Ga-NODAGA-folate conjugates.
    Fani M; Tamma ML; Nicolas GP; Lasri E; Medina C; Raynal I; Port M; Weber WA; Maecke HR
    Mol Pharm; 2012 May; 9(5):1136-45. PubMed ID: 22497506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved therapeutic activity of folate-targeted liposomal doxorubicin in folate receptor-expressing tumor models.
    Gabizon A; Tzemach D; Gorin J; Mak L; Amitay Y; Shmeeda H; Zalipsky S
    Cancer Chemother Pharmacol; 2010 May; 66(1):43-52. PubMed ID: 19779718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and biological evaluation of a folate-targeted rhaponticin conjugate.
    Liang X; Sun Y; Zeng W; Liu L; Ma X; Zhao Y; Fan J
    Bioorg Med Chem; 2013 Jan; 21(1):178-85. PubMed ID: 23177726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Folate targeting enables durable and specific antitumor responses from a therapeutically null tubulysin B analogue.
    Leamon CP; Reddy JA; Vetzel M; Dorton R; Westrick E; Parker N; Wang Y; Vlahov I
    Cancer Res; 2008 Dec; 68(23):9839-44. PubMed ID: 19047164
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of in vivo disulfide-reduction mediated drug release in mouse kidneys.
    Yang JJ; Kularatne SA; Chen X; Low PS; Wang E
    Mol Pharm; 2012 Feb; 9(2):310-7. PubMed ID: 22171616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment with low-dose interferon-alpha restores the balance between matrix metalloproteinase-9 and E-cadherin expression in human transitional cell carcinoma of the bladder.
    Slaton JW; Karashima T; Perrotte P; Inoue K; Kim SJ; Izawa J; Kedar D; McConkey DJ; Millikan R; Sweeney P; Yoshikawa C; Shuin T; Dinney CP
    Clin Cancer Res; 2001 Sep; 7(9):2840-53. PubMed ID: 11555602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative Gene Expression Analyses Identify Luminal and Basal Subtypes of Canine Invasive Urothelial Carcinoma That Mimic Patterns in Human Invasive Bladder Cancer.
    Dhawan D; Paoloni M; Shukradas S; Choudhury DR; Craig BA; Ramos-Vara JA; Hahn N; Bonney PL; Khanna C; Knapp DW
    PLoS One; 2015; 10(9):e0136688. PubMed ID: 26352142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro and in vivo evaluation of (99m)Tc-DO3A-EA-Folate for receptor-mediated targeting of folate positive tumors.
    Mishra G; Hazari PP; Kumar N; Mishra AK
    J Drug Target; 2011 Nov; 19(9):761-9. PubMed ID: 21425922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical trial of vinblastine in dogs with transitional cell carcinoma of the urinary bladder.
    Arnold EJ; Childress MO; Fourez LM; Tan KM; Stewart JC; Bonney PL; Knapp DW
    J Vet Intern Med; 2011; 25(6):1385-90. PubMed ID: 22092632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploratory study of 99mTc-EC20 imaging for identifying patients with folate receptor-positive solid tumors.
    Fisher RE; Siegel BA; Edell SL; Oyesiku NM; Morgenstern DE; Messmann RA; Amato RJ
    J Nucl Med; 2008 Jun; 49(6):899-906. PubMed ID: 18483093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical evaluation of mitoxantrone and piroxicam in a canine model of human invasive urinary bladder carcinoma.
    Henry CJ; McCaw DL; Turnquist SE; Tyler JW; Bravo L; Sheafor S; Straw RC; Dernell WS; Madewell BR; Jorgensen L; Scott MA; Higginbotham ML; Chun R
    Clin Cancer Res; 2003 Feb; 9(2):906-11. PubMed ID: 12576466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative evaluation of the biological properties of reducible and acid-sensitive folate prodrugs of a highly potent doxorubicin derivative.
    Abu Ajaj K; El-Abadla N; Welker P; Azab S; Zeisig R; Fichtner I; Kratz F
    Eur J Cancer; 2012 Sep; 48(13):2054-65. PubMed ID: 21937219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regioselective synthesis of folate receptor-targeted agents derived from epothilone analogs and folic acid.
    Vlahov IR; Vite GD; Kleindl PJ; Wang Y; Santhapuram HK; You F; Howard SJ; Kim SH; Lee FF; Leamon CP
    Bioorg Med Chem Lett; 2010 Aug; 20(15):4578-81. PubMed ID: 20594844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.